Advertisement

Employment/Membership › Details
BRAIN–Linnig L: management, 202010– CFO before Head of Financing, Controlling + Legal joined 4/17
![]() |
Period | 2020-10-01 |
![]() |
Organisation | BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN) |
Group | BRAIN (Group) | |
![]() |
Product | industrial biotechnology |
Product 2 | industrial enzyme | |
![]() |
Person | Linnig, Lukas (BRAIN 202010– CFO before Head of Financing, Controlling + Legal joined 201704) |
Person 2 | Bender, Manfred (BRAIN 201812–202009 CFO before Pfeiffer Vacuum CEO before CFO LEFT 9/20) | |
BRAIN AG. (5/7/20). "Press Release: Change in the Management Board of BRAIN AG".
Chief Financial Officer Manfred Bender is leaving the biotechnology company at the end of the current financial year. Lukas Linnig to become the new CFO.
The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Financial Officer Manfred Bender will leave the company at his own request on 30 September 2020. Mr Bender will take on a new assignment and has therefore asked the Supervisory Board to terminate his contract prematurely. The Supervisory Board has complied with this request.
The new Chief Financial Officer will be Lukas Linnig, the current Head of Finance, Controlling and Legal. Linnig has worked for the company since April 2017 and he previously advised BRAIN as a consultant during the IPO.
Dr Georg Kellinghusen, Chairman of the Supervisory Board, says: “We regret Mr Bender's decision, but we respect it. We thank him for his great contribution and commitment to BRAIN AG. With Lukas Linnig, we have found a successor who knows the company extremely well. There is sufficient time for an orderly transition until Mr Bender leaves the company.”
Adriaan Moelker, CEO BRAIN AG, commented: “Lukas Linnig has proven that he has all the skills for a strong CFO. I am very pleased to have him on the management board and I am confident that with Lukas’ appointment we are taking an important step in building a strong future-orientated team.”
Portrait of Lukas Linnig, BRAIN AG
Press Image
Lukas Linnig
Low resolution
High resolution
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the “Tailor-Made Solutions” cooperation business), and the company’s own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
Media Contact
Dr. Stephanie Konle
pr@brain-biotech.com
+49 (0)6251-9331-70
Record changed: 2020-11-20 |
Advertisement
![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
More documents for BRAIN (Group)
- [1] BRAIN AG. (1/7/21). "Press Release: BRAIN Group Expands Its US Products Business with the Successful Acquisition of Biosun Biochemicals Inc.". Zwingenberg....
- [2] BRAIN AG. (7/7/20). "Press Release: Change in the Management Board of BRAIN AG. Chief Business Officer Ludger Roedder Is Leaving the Executive Board with Immediate Effect". Zwingenberg....
- [3] BRAIN AG. (7/2/20). "Press Release: BRAIN AG Purchases the Outstanding 24.7% Minority Stake of WeissBioTech GmbH". Zwingenberg....
- [4] BRAIN AG. (6/4/20). "Press Release: BRAIN AG Successfully Placed New Capital for the Financing of further Growth". Zwingenberg....
- [5] BRAIN AG. (6/3/20). "Press Release: BRAIN AG Resolves on a Cash Capital Increase from Authorised Capital"....
- [6] BRAIN AG. (5/7/20). "Press Release: Change in the Management Board of BRAIN AG"....
- [7] BRAIN AG. (12/2/19). "Press Release: New Chairman of the Management Board – Adriaan Moelker Takes Over from Dr Jürgen Eck". Zwingenberg....
- [8] BRAIN AG. (5/29/19). "Press Release: BRAIN AG Achieves Significant Growth in the First Half of the 2018/19 Financial Year". Zwingenberg....
- [9] BRAIN AG. (3/12/19). "Press Release: Global Beverage Company Has Joined the DOLCE Program. New Member Gains Access to DOLCE Sweet Solutions in the Field of Beverages". Zwingenberg, Potsdam & La Madeleine Cedex....
- [10] BRAIN AG. (12/14/18). "Press Release: BRAIN Achieves Double-digit Growth in Total Operating Performance and Revenues in the 2017/18 Financial Year". Zwingenberg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
» top